Effect of Single Dose of RANKL Antibody Treatment on Acute Charcot Neuro-osteoarthropathy of the Foot

Charcot neuro-osteoarthropathy is a rare condition that affects subjects with diabetes with neuropathy. Although the underlying pathophysiology is largely unknown, increased receptor activator of nuclear factor κ-B ligand (RANKL) activation in Charcot neuro-osteoarthropathy has been observed. The monoclonal RANKL antibody treatment (denosumab, Prolia) could reduce osteoporosis-related fractures. Here, Busch-Westbroek et al examine the effect of the RANKL antibody treatment on fracture resolution time and clinical outcomes in acute Charcot neuro-osteoarthropathy.